An Update Regarding Seasonal Illnesses

To help prevent the spread of seasonal respiratory illnesses, we strongly encourage all visitors to wear a mask while in ambulatory clinics or inpatient units. Surgical masks are available at hospital and clinic entrances. Patients with respiratory illnesses should also wear masks. Thank you for helping protect our patients, staff, and community.

Langue

PROFESS

PROFESS: Prevention Regimen For Effectively avoiding Second Strokes

Sponsor: Boehringer Ingelheim

Investigators: Carlos Kase MD, Viken Babikian MD, Jose Romero MD

PRoFESS Results Announced At XVII European Stroke Conference on Thursday 15 May 2008.

The PRoFESS trial, a large clinical research study for secondary stroke prevention showed that the recurrent stroke event rates for Aggrenox and clopidogrel were similar. In further exploratory analysis of the main secondary endpoint of the composite of stroke, myocardial infarction or vascular death, AGGRENOX and clopidogrel showed similar outcomes (13.1% versus 13.1%). In PRoFESS, the AGGRENOX arm had a higher number of hemorrhagic strokes compared to clopidogrel (0.8% and 0.4%, respectively) while ischemic stroke recurrences were less frequent in the AGGRENOX arm compared to the clopidogrel arm (7.7% and 7.9%, respectively). A post-hoc analysis showed comparable numbers of death and disabling strokes and a similar neurological outcome as measured by the modified Rankin Scale at three months after the recurrent stroke and at the end of the PRoFESS trial between the two treatment arms.